Nakayama, Izumi
Goto, Atsushi http://orcid.org/0000-0003-0669-654X
Hayashino, Yasuaki
Suzuki, Hikari
Yamazaki, Katsuya
Izumi, Kazuo
Noda, Mitsuhiko
Funding for this research was provided by:
Japan Agency for Medical Research and Development (Practical Research Project for Life-Style related Diseases including CVD, Diabetes)
Ministry of Health, Labour and Welfare (H25-016)
the Japan Diabetes Foundation
Article History
Received: 19 December 2021
Accepted: 15 February 2022
First Online: 12 March 2022
Declarations
:
: Yasuaki Hayashino received grants from Ono Pharmaceutical Co., Ltd., Grants-in-Aid for Scientific Research, consulting fees from Ono Pharmaceutical Co., Ltd., honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Ltd., Merck & Co., Inc., Sanofi KK., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Kowa Pharmaceutical Co., Ltd, Boehringer Ingelheim, Novo Nordisk Pharma Ltd., Bayer Pharma, Sumitomo Dainippon Pharma Co., Ltd., and participated on advisory board of Novo Nordisk Pharma Ltd. The remaining authors have no conflicts of interest to declare.
: This study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Yokohama City University institutional review board.
: The requirement for informed consent was waived due to the nature of the study.
: The data are not publicly available due to them containing information that could compromise research participant privacy/consent.